AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04829981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change interventions
Description: Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
Study NCT05720754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Study NCT05720754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Study NCT05720754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated eye mask
Description: Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
Study NCT05720754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated eye mask
Description: Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
Study NCT05413577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
Study NCT05753397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
Study NCT05570981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laryngeal sensitivity testing
Description: Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
Study NCT00068991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV skills training program and questionnaire
Description: Two-hour weekly skills training sessions followed by evaluation questionnaire
Study NCT00068991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-level stigma reduction program
Description: Two-hour training sessions focusing on anti-stigma and anti-discrimination
Study NCT00068991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cross-sectional survey
Description: Survey evaluation of community attitudes towards HIV
Study NCT04438187 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: antimicrobial initiation
Description: antimicrobial initiation based on protocol assignment.
Study NCT04605913 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Modified GCN+TTF treatment
Description: The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
Study NCT04729712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion
Description: Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
Study NCT04729712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgeon-administered video-assisted Paravertebral block with catheter insertion
Description: Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
Study NCT06636370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography (CEM)
Description: This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
Study NCT06636370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbreviated MRI (AB-MRI)
Description: This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
Study NCT05289648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib oral capsule
Description: Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
Study NCT05115123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine
Study NCT05115123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06212583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: niraparib/abiraterone acetate
Description: Patients on Arm 2 to receive drug for 6 months
Study NCT06212583 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic ablative radiation therapy (SABR)
Description: Both arms will receive SABR
Study NCT06212583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All ADT is provided as best prescribed for patient per their medical oncologist.
Study NCT05245513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Community Center Linkage (RCCL)
Description: A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
Study NCT05245513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition (CC)
Description: A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
Study NCT04765592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Arch Modeler Embedded Branch Stent Graft System
Description: The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
Study NCT04524338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Brain Stimulation Devices attached to scalp
Study NCT05692973 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Role of Knowledge Retrieval
Description: Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
Study NCT05692973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role of Knowledge Retrieval
Description: Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
Study NCT05692973 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inference Intervention
Description: The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
Study NCT05692973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inference Intervention
Description: The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
Study NCT05367531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Study NCT05367531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Injector
Description: For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Study NCT05367531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled
Description: For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Study NCT06337201 — intervention group
Intervention type: DEVICE
Intervention: Test of the application Min Memoria
Description: Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
Study NCT04988373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified aligner appliance
Description: Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
Study NCT04988373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional fixed appliance
Description: Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
Study NCT06159478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: Binimetinib 45mg is orally administered twice daily.
Study NCT06377189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings
Description: The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective.
Study NCT06377189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm - Treatment As Usual (TAU)
Description: PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
Study NCT04253132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolfenamic Acid
Description: Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
Study NCT04253132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebo
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
Study NCT05463133 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pheripheral blood stem cells
Description: Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
Study NCT05463133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pheripheral blood stem cells
Description: Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab-Izsg
Description: Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tociluzumab
Description: Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociluzumab
Description: Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
Study NCT05463133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
Study NCT04894240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monepantel
Description: Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
Study NCT04890990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.
Study NCT05000528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education
Description: In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.